Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study

BMC Medicine

W. John Edmunds¹  Stefan Flasche¹  Anton Camacho¹  Marc Baguelin¹ 

[1]Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK

关键词: Vaccination;    Respiratory infections;    Influenza;    Cost-effectiveness;    Children;   

Others  :  1228305
DOI  :  10.1186/s12916-015-0452-y

 received in 2015-05-12, accepted in 2015-08-14,  发布年份 2015

【 摘 要 】

Background

The present study aims to evaluate the cost-effectiveness of extending the pre-2013 influenza immunisation programme for high-risk and elderly individuals to those at low risk of developing complications following infection with seasonal influenza.

Methods

We performed an economic evaluation comparing different extensions of the pre-2013 influenza programme to seven possible age groups of low-risk individuals (aged 2–4 years, 50–64 years, 5–16 years, 2–4 and 50–64 years, 2–16 years, 2–16 and 50–64 years, and 2–64 years). These extensions are evaluated incrementally on four base scenarios (no vaccination, risk group only with coverage as observed between 1995 and 2009, risk group and 65+, and risk group with 75 % coverage and 65+). Impact of vaccination is assessed using a transmission model built and parameterised from a previously published study. The study population is all individuals of all ages in England and Wales representing an average total of 52.6 million people over 14 influenza seasons (1995–2009).

Results

The influenza programme (risk group and elderly) prior to 2013 is likely to be cost effective (incremental cost effectiveness ratio: 7,475 £/QALY, net benefit: 253 M£ [15–829]). Extension to any one of the low-risk target groups defined earlier is likely to be cost-effective. However, strategies that do not include vaccination of school-aged children are less likely to be cost-effective. The most efficient strategy is extension to the 5–16 year age group while universal vaccination (extension to all low-risk individuals over 2 years) will achieve the highest net benefit. While extension to the 2–16 year age group is likely to be very cost effective, the cost-effectiveness of extensions beyond 2–16 years is very uncertain. Extension to the 5–16 year age group would likely remain cost-effective even without herd immunity effects to other age groups. As our study includes a strong historical component, our results depend on the efficacy of the influenza vaccine remaining at levels similar to the ones achieved in the past over a long-period of time (assumed to vary between 28 % and 70 % depending of the circulating strains and age groups).

Conclusions

Making use of surveillance data from over a decade in conjunction with a dynamic model, we find that vaccination of children in the United Kingdom is likely to be highly cost-effective, not only for their own benefit but also to reduce the disease burden in the rest of the community.

【 授权许可】

   
2015 Baguelin et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Influenza Vaccines – WHO Position Paper. WHO, Geneva; 2005.
• [2]Mereckiene J, Cotter S, D’Ancona F, Giambi C, Nicoll A, Lévy-Bruhl D et al.. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008–2009. Eurosurveillance. 2010; 15:1-10.
• [3]Weekly epidemiological record. WHO, Geneva; 2012. 21 (pp 201–216)
• [4]Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008; 26:5321-30.
• [5]Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol. 2009; 170:679-86.
• [6]Cauchemez S, Valleron A-J, Boëlle P-Y, Flahault A, Ferguson NM. Estimating the impact of school closure on influenza transmission from Sentinel data. Nature. 2008; 452:750-4.
• [7]Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine. 2012; 30:3459-62.
• [8]Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJD et al.. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010; 303:943-50.
• [9]Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med. 2013; 10:e1001527.
• [10]JCVI statement on the annual influenza vaccination programme – extension of the programme to children. 2012. http://webarchive. nationalarchives.gov.uk/20130402145952/http://media.dh.gov.uk/network/261/files/2012/07/jcvi-statement-on-the-annual-influenza-vaccination-programme-25-july-2012.pdf
• [11]Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policy. J Infect. 2014; 68:363-71.
• [12]National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2013. https://www. nice.org.uk/article/pmg9/chapter/foreword
• [13]Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S et al.. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008; 167:775-85.
• [14]Camacho A, Eames K, Adler A, Funk S, Edmunds J. Estimation of the quality of life effect of seasonal influenza infection in the UK with the internet-based Flusurvey cohort: an observational cohort study. Lancet. 2013; 382:S8.
• [15]Adler AJ, Eames KTD, Funk S, Edmunds WJ. Incidence and risk factors for influenza-like-illness in the UK: online surveillance using Flusurvey. BMC Infect Dis. 2014; 14:232. BioMed Central Full Text
• [16]Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer G a, Al-Ansary L A, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;(7):CD001269.
• [17]Fleming DM, Andrews NJ, Ellis JS, Bermingham A, Sebastianpillai P, Elliot AJ et al.. Estimating influenza vaccine effectiveness using routinely collected laboratory data. J Epidemiol Community Health. 2010; 64:1062-7.
• [18]Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ et al.. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine. 2009; 27:1101-10.
• [19]National Health Service England. Enhanced Services Specification: Seasonal Influenza and Pneumococcal Immunisation Enhanced Service. 2014. http://www. england.nhs.uk/wp-content/uploads/2014/06/flu-pneumo-immu-spec.pdf
• [20]National Health Service England. General Medical Services Statement of Financial Entitlements Directions 2014. 2014. https://www. gov.uk/government/uploads/system/uploads/attachment_data/file/299591/SFE_amend_directions_2014.pdf
• [21]Van Hoek AJ, Underwood A, Jit M, Miller E, Edmunds WJ. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS One. 2011; 6:e17030.
• [22]Siddiqui MR, Edmunds WJ. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis. 2008; 14:267-74.
• [23]Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol. 2004; 19:365-75.
• [24]Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998; 316:736-41.
• [25]Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ et al.. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med. 2014; 2:445-54.
• [26]Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R et al.. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008; 5:e74.
• [27]Baguelin M, Van Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine. 2010; 28:2370-84.
• [28]Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998; 17:873-90.
• [29]Mogasale V, Barendregt J. Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive. Aust N Z J Public Health. 2011; 35:180-6.
• [30]Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine. 2010; 28:7620-5.
• [31]Newall AT, Scuffham PA, Kelly H, Harsley S, Macintyre CR. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia. Vaccine. 2008; 26:2142-53.
• [32]Aballéa S, De Juanes JR, Barbieri M, Martin M, Chancellor J, Oyagüez I et al.. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain. Vaccine. 2007; 25:6900-10.
• [33]Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R et al.. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health. 2007; 10:98-116.
• [34]Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V et al.. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch Pediatr Adolesc Med. 2011; 165:112-8.
• [35]Salleras L, Navas E, Domínguez A, Ibáñez D, Prat A, Garrido P et al.. Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices. Vaccine. 2009; 27:3454-8.
• [36]Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A et al.. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Vaccine. 2008; 26:2841-8.
• [37]Schmier J, Li S, King JC, Nichol K, Mahadevia PJ. Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial. Health Aff (Millwood). 2008; 27:w96-104.
• [38]Pradas-Velasco R, Antoñanzas-Villar F, Martínez-Zárate MP. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination. Pharmacoeconomics. 2008; 26:45-56.
• [39]Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine. 2007; 25:8010-20.
• [40]Marchetti M, Kühnel UM, Colombo GL, Esposito S, Principi N. Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Hum Vaccin. 2007; 3:14-22.
• [41]Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM et al.. Economic appraisal of Ontario’s Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med. 2010; 7:e1000256.
• [42]Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI, Widdowson M-A. Influenza cost and cost-effectiveness studies globally – a review. Vaccine. 2013; 31:5339-48.